Global and United States RNA Interference (RNAi) Drug Delivery Market Report & Forecast 2024-2031

Report ID: 1839394 | Published Date: Oct 2024 | No. of Page: 106 | Base Year: 2023 | Rating: 4.7 | Webstory: Check our Web story
1 Study Coverage
    1.1 RNA Interference (RNAi) Drug Delivery Product Introduction
    1.2 Global RNA Interference (RNAi) Drug Delivery Outlook 2017 VS 2022 VS 2028
        1.2.1 Global RNA Interference (RNAi) Drug Delivery Sales in US$ Million for the Year 2017-2028
        1.2.2 Global RNA Interference (RNAi) Drug Delivery Sales in Volume for the Year 2017-2028
    1.3 United States RNA Interference (RNAi) Drug Delivery Outlook 2017 VS 2022 VS 2028
        1.3.1 United States RNA Interference (RNAi) Drug Delivery Sales in US$ Million for the Year 2017-2028
        1.3.2 United States RNA Interference (RNAi) Drug Delivery Sales in Volume for the Year 2017-2028
    1.4 RNA Interference (RNAi) Drug Delivery Market Size, United States VS Global, 2017 VS 2022 VS 2028
        1.4.1 The Market Share of United States RNA Interference (RNAi) Drug Delivery in Global, 2017 VS 2022 VS 2028
        1.4.2 The Growth Rate of RNA Interference (RNAi) Drug Delivery Market Size, United States VS Global, 2017 VS 2022 VS 2028
    1.5 RNA Interference (RNAi) Drug Delivery Market Dynamics
        1.5.1 RNA Interference (RNAi) Drug Delivery Industry Trends
        1.5.2 RNA Interference (RNAi) Drug Delivery Market Drivers
        1.5.3 RNA Interference (RNAi) Drug Delivery Market Challenges
        1.5.4 RNA Interference (RNAi) Drug Delivery Market Restraints
    1.6 Study Objectives
    1.7 Years Considered
2 Market by Type
    2.1 RNA Interference (RNAi) Drug Delivery Market Segment by Type
        2.1.1 Nanoparticle Drug Delivery Technology
        2.1.2 Pulmonary Drug Delivery Technology
        2.1.3 Nucleic Acid Drug Delivery Technology
        2.1.4 Aptamer Drug Delivery Technology
    2.2 Global RNA Interference (RNAi) Drug Delivery Market Size by Type
        2.2.1 Global RNA Interference (RNAi) Drug Delivery Sales in Value, by Type (2017, 2022 & 2028)
        2.2.2 Global RNA Interference (RNAi) Drug Delivery Sales in Volume, by Type (2017, 2022 & 2028)
        2.2.3 Global RNA Interference (RNAi) Drug Delivery Average Selling Price (ASP) by Type (2017, 2022 & 2028)
    2.3 United States RNA Interference (RNAi) Drug Delivery Market Size by Type
        2.3.1 United States RNA Interference (RNAi) Drug Delivery Sales in Value, by Type (2017, 2022 & 2028)
        2.3.2 United States RNA Interference (RNAi) Drug Delivery Sales in Volume, by Type (2017, 2022 & 2028)
        2.3.3 United States RNA Interference (RNAi) Drug Delivery Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
    3.1 RNA Interference (RNAi) Drug Delivery Market Segment by Application
        3.1.1 Infectious Diseases
        3.1.2 Cardiology
        3.1.3 Oncology
        3.1.4 Neurology
        3.1.5 Ophthalmology
        3.1.6 Metabolic Disorders
    3.2 Global RNA Interference (RNAi) Drug Delivery Market Size by Application
        3.2.1 Global RNA Interference (RNAi) Drug Delivery Sales in Value, by Application (2017, 2022 & 2028)
        3.2.2 Global RNA Interference (RNAi) Drug Delivery Sales in Volume, by Application (2017, 2022 & 2028)
        3.3.3 Global RNA Interference (RNAi) Drug Delivery Average Selling Price (ASP) by Application (2017, 2022 & 2028)
    3.3 United States RNA Interference (RNAi) Drug Delivery Market Size by Application
        3.3.1 United States RNA Interference (RNAi) Drug Delivery Sales in Value, by Application (2017, 2022 & 2028)
        3.3.2 United States RNA Interference (RNAi) Drug Delivery Sales in Volume, by Application (2017, 2022 & 2028)
        3.3.3 United States RNA Interference (RNAi) Drug Delivery Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global RNA Interference (RNAi) Drug Delivery Competitor Landscape by Company
    4.1 Global RNA Interference (RNAi) Drug Delivery Market Size by Company
        4.1.1 Top Global RNA Interference (RNAi) Drug Delivery Manufacturers Ranked by Revenue (2021)
        4.1.2 Global RNA Interference (RNAi) Drug Delivery Revenue by Manufacturer (2017-2022)
        4.1.3 Global RNA Interference (RNAi) Drug Delivery Sales by Manufacturer (2017-2022)
        4.1.4 Global RNA Interference (RNAi) Drug Delivery Price by Manufacturer (2017-2022)
    4.2 Global RNA Interference (RNAi) Drug Delivery Concentration Ratio (CR)
        4.2.1 RNA Interference (RNAi) Drug Delivery Market Concentration Ratio (CR) (2017-2022)
        4.2.2 Global Top 5 and Top 10 Largest Manufacturers of RNA Interference (RNAi) Drug Delivery in 2021
        4.2.3 Global RNA Interference (RNAi) Drug Delivery Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    4.3 Global RNA Interference (RNAi) Drug Delivery Manufacturing Base Distribution, Product Type
        4.3.1 Global RNA Interference (RNAi) Drug Delivery Manufacturers, Headquarters and Distribution of Producing Region
        4.3.2 Manufacturers RNA Interference (RNAi) Drug Delivery Product Type
        4.3.3 Date of International Manufacturers Enter into RNA Interference (RNAi) Drug Delivery Market
    4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
    4.5 United States RNA Interference (RNAi) Drug Delivery Market Size by Company
        4.5.1 Top RNA Interference (RNAi) Drug Delivery Players in United States, Ranked by Revenue (2021)
        4.5.2 United States RNA Interference (RNAi) Drug Delivery Revenue by Players (2020, 2021 & 2022)
        4.5.3 United States RNA Interference (RNAi) Drug Delivery Sales by Players (2020, 2021 & 2022)
5 Global RNA Interference (RNAi) Drug Delivery Market Size by Region
    5.1 Global RNA Interference (RNAi) Drug Delivery Market Size by Region: 2017 VS 2022 VS 2028
    5.2 Global RNA Interference (RNAi) Drug Delivery Market Size in Volume by Region (2017-2028)
        5.2.1 Global RNA Interference (RNAi) Drug Delivery Sales in Volume by Region: 2017-2022
        5.2.2 Global RNA Interference (RNAi) Drug Delivery Sales in Volume Forecast by Region (2023-2028)
    5.3 Global RNA Interference (RNAi) Drug Delivery Market Size in Value by Region (2017-2028)
        5.3.1 Global RNA Interference (RNAi) Drug Delivery Sales in Value by Region: 2017-2022
        5.3.2 Global RNA Interference (RNAi) Drug Delivery Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
    6.1 North America
        6.1.1 North America RNA Interference (RNAi) Drug Delivery Market Size YoY Growth 2017-2028
        6.1.2 North America RNA Interference (RNAi) Drug Delivery Market Facts & Figures by Country (2017, 2022 & 2028)
        6.1.3 U.S.
        6.1.4 Canada
    6.2 Asia-Pacific
        6.2.1 Asia-Pacific RNA Interference (RNAi) Drug Delivery Market Size YoY Growth 2017-2028
        6.2.2 Asia-Pacific RNA Interference (RNAi) Drug Delivery Market Facts & Figures by Region (2017, 2022 & 2028)
        6.2.3 China
        6.2.4 Japan
        6.2.5 South Korea
        6.2.6 India
        6.2.7 Australia
        6.2.8 Taiwan
        6.2.9 Indonesia
        6.2.10 Thailand
        6.2.11 Malaysia
        6.2.12 Philippines
    6.3 Europe
        6.3.1 Europe RNA Interference (RNAi) Drug Delivery Market Size YoY Growth 2017-2028
        6.3.2 Europe RNA Interference (RNAi) Drug Delivery Market Facts & Figures by Country (2017, 2022 & 2028)
        6.3.3 Germany
        6.3.4 France
        6.3.5 U.K.
        6.3.6 Italy
        6.3.7 Russia
    6.4 Latin America
        6.4.1 Latin America RNA Interference (RNAi) Drug Delivery Market Size YoY Growth 2017-2028
        6.4.2 Latin America RNA Interference (RNAi) Drug Delivery Market Facts & Figures by Country (2017, 2022 & 2028)
        6.4.3 Mexico
        6.4.4 Brazil
        6.4.5 Argentina
    6.5 Middle East and Africa
        6.5.1 Middle East and Africa RNA Interference (RNAi) Drug Delivery Market Size YoY Growth 2017-2028
        6.5.2 Middle East and Africa RNA Interference (RNAi) Drug Delivery Market Facts & Figures by Country (2017, 2022 & 2028)
        6.5.3 Turkey
        6.5.4 Saudi Arabia
        6.5.5 U.A.E
7 Company Profiles
    7.1 Metabolic disorders
        7.1.1 Metabolic disorders Corporation Information
        7.1.2 Metabolic disorders Description and Business Overview
        7.1.3 Metabolic disorders RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
        7.1.4 Metabolic disorders RNA Interference (RNAi) Drug Delivery Products Offered
        7.1.5 Metabolic disorders Recent Development
    7.2 Alnylam Pharmaceuticals Inc
        7.2.1 Alnylam Pharmaceuticals Inc Corporation Information
        7.2.2 Alnylam Pharmaceuticals Inc Description and Business Overview
        7.2.3 Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
        7.2.4 Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Products Offered
        7.2.5 Alnylam Pharmaceuticals Inc Recent Development
    7.3 Merck & Co. Inc
        7.3.1 Merck & Co. Inc Corporation Information
        7.3.2 Merck & Co. Inc Description and Business Overview
        7.3.3 Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
        7.3.4 Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Products Offered
        7.3.5 Merck & Co. Inc Recent Development
    7.4 Access Pharmaceuticals Inc
        7.4.1 Access Pharmaceuticals Inc Corporation Information
        7.4.2 Access Pharmaceuticals Inc Description and Business Overview
        7.4.3 Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
        7.4.4 Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Products Offered
        7.4.5 Access Pharmaceuticals Inc Recent Development
    7.5 Dicerna Pharmaceuticals Inc
        7.5.1 Dicerna Pharmaceuticals Inc Corporation Information
        7.5.2 Dicerna Pharmaceuticals Inc Description and Business Overview
        7.5.3 Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
        7.5.4 Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Products Offered
        7.5.5 Dicerna Pharmaceuticals Inc Recent Development
    7.6 Calondo Pharmaceuticals Inc
        7.6.1 Calondo Pharmaceuticals Inc Corporation Information
        7.6.2 Calondo Pharmaceuticals Inc Description and Business Overview
        7.6.3 Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
        7.6.4 Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Products Offered
        7.6.5 Calondo Pharmaceuticals Inc Recent Development
    7.7 Marina Biotech Inc
        7.7.1 Marina Biotech Inc Corporation Information
        7.7.2 Marina Biotech Inc Description and Business Overview
        7.7.3 Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
        7.7.4 Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Products Offered
        7.7.5 Marina Biotech Inc Recent Development
    7.8 RXi Pharmaceuticals Corp
        7.8.1 RXi Pharmaceuticals Corp Corporation Information
        7.8.2 RXi Pharmaceuticals Corp Description and Business Overview
        7.8.3 RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
        7.8.4 RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Products Offered
        7.8.5 RXi Pharmaceuticals Corp Recent Development
    7.9 Quark Pharmaceuticals Inc
        7.9.1 Quark Pharmaceuticals Inc Corporation Information
        7.9.2 Quark Pharmaceuticals Inc Description and Business Overview
        7.9.3 Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
        7.9.4 Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Products Offered
        7.9.5 Quark Pharmaceuticals Inc Recent Development
    7.10 Silence Therapeutics plc
        7.10.1 Silence Therapeutics plc Corporation Information
        7.10.2 Silence Therapeutics plc Description and Business Overview
        7.10.3 Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
        7.10.4 Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Products Offered
        7.10.5 Silence Therapeutics plc Recent Development
    7.11 Tacere Therapeutics Inc
        7.11.1 Tacere Therapeutics Inc Corporation Information
        7.11.2 Tacere Therapeutics Inc Description and Business Overview
        7.11.3 Tacere Therapeutics Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
        7.11.4 Tacere Therapeutics Inc RNA Interference (RNAi) Drug Delivery Products Offered
        7.11.5 Tacere Therapeutics Inc Recent Development
    7.12 PhaseRx Inc
        7.12.1 PhaseRx Inc Corporation Information
        7.12.2 PhaseRx Inc Description and Business Overview
        7.12.3 PhaseRx Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
        7.12.4 PhaseRx Inc Products Offered
        7.12.5 PhaseRx Inc Recent Development
    7.13 Sirnaomics Inc
        7.13.1 Sirnaomics Inc Corporation Information
        7.13.2 Sirnaomics Inc Description and Business Overview
        7.13.3 Sirnaomics Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
        7.13.4 Sirnaomics Inc Products Offered
        7.13.5 Sirnaomics Inc Recent Development
    7.14 Traversa Therapeutics Inc
        7.14.1 Traversa Therapeutics Inc Corporation Information
        7.14.2 Traversa Therapeutics Inc Description and Business Overview
        7.14.3 Traversa Therapeutics Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue and Gross Margin (2017-2022)
        7.14.4 Traversa Therapeutics Inc Products Offered
        7.14.5 Traversa Therapeutics Inc Recent Development
8 Industry Chain and Sales Channels Analysis
    8.1 RNA Interference (RNAi) Drug Delivery Industry Chain Analysis
    8.2 RNA Interference (RNAi) Drug Delivery Key Raw Materials
        8.2.1 Key Raw Materials
        8.2.2 RNA Interference (RNAi) Drug Delivery Distributors
    8.3 RNA Interference (RNAi) Drug Delivery Production Mode & Process
    8.4 RNA Interference (RNAi) Drug Delivery Sales and Marketing
        8.4.1 RNA Interference (RNAi) Drug Delivery Sales Channels
        8.4.2 RNA Interference (RNAi) Drug Delivery Distributors
    8.5 RNA Interference (RNAi) Drug Delivery Customers
9 Research Findings and Conclusion
10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer
List of Tables
    Table 1. RNA Interference (RNAi) Drug Delivery CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
    Table 2. RNA Interference (RNAi) Drug Delivery Market Trends
    Table 3. RNA Interference (RNAi) Drug Delivery Market Drivers
    Table 4. RNA Interference (RNAi) Drug Delivery Market Challenges
    Table 5. RNA Interference (RNAi) Drug Delivery Market Restraints
    Table 6. Global RNA Interference (RNAi) Drug Delivery Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States RNA Interference (RNAi) Drug Delivery Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global RNA Interference (RNAi) Drug Delivery Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States RNA Interference (RNAi) Drug Delivery Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top RNA Interference (RNAi) Drug Delivery Manufacturers in Global Market, Ranking by Revenue (2021)
    Table 11. Global RNA Interference (RNAi) Drug Delivery Revenue by Manufacturer, (US$ Million), 2017-2022
    Table 12. Global RNA Interference (RNAi) Drug Delivery Revenue Share by Manufacturer, 2017-2022
    Table 13. Global RNA Interference (RNAi) Drug Delivery Sales by Manufacturer, (K Units), 2017-2022
    Table 14. Global RNA Interference (RNAi) Drug Delivery Sales Share by Manufacturer, 2017-2022
    Table 15. Global RNA Interference (RNAi) Drug Delivery Price by Manufacturer (2017-2022) & (USD/Unit)
    Table 16. Global RNA Interference (RNAi) Drug Delivery Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 17. Global RNA Interference (RNAi) Drug Delivery by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNA Interference (RNAi) Drug Delivery as of 2021)
    Table 18. Top Players of RNA Interference (RNAi) Drug Delivery in Global Market, Headquarters and Distribution of Producing Region
    Table 19. Manufacturers RNA Interference (RNAi) Drug Delivery Product Type
    Table 20. Date of International Manufacturers Enter into RNA Interference (RNAi) Drug Delivery Market
    Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 22. Top RNA Interference (RNAi) Drug Delivery Players in United States Market, Ranking by Revenue (2021)
    Table 23. United States RNA Interference (RNAi) Drug Delivery Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 24. United States RNA Interference (RNAi) Drug Delivery Revenue Share by Players, 2020, 2021 & 2022
    Table 25. United States RNA Interference (RNAi) Drug Delivery Sales by Players, (K Units), 2020, 2021 & 2022
    Table 26. United States RNA Interference (RNAi) Drug Delivery Sales Share by Players, 2020, 2021 & 2022
    Table 27. Global RNA Interference (RNAi) Drug Delivery Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 28. Global RNA Interference (RNAi) Drug Delivery Sales in Volume by Region (2017-2022) & (K Units)
    Table 29. Global RNA Interference (RNAi) Drug Delivery Sales in Volume Forecast by Region (2023-2028) & (K Units)
    Table 30. Global RNA Interference (RNAi) Drug Delivery Sales in Value by Region (2017-2022) & (US$ Million)
    Table 31. Global RNA Interference (RNAi) Drug Delivery Sales in Value Forecast by Region (2023-2028) & (US$ Million)
    Table 32. North America RNA Interference (RNAi) Drug Delivery Sales in Volume by Country (2017-2028) & (K Units)
    Table 33. North America RNA Interference (RNAi) Drug Delivery Sales in Value by Country (2017-2028) & (US$ Million)
    Table 34. Asia Pacific RNA Interference (RNAi) Drug Delivery Sales in Volume by Region (2017-2028) & (K Units)
    Table 35. Asia Pacific RNA Interference (RNAi) Drug Delivery Sales in Value by Region (2017-2028) & (US$ Million)
    Table 36. Europe RNA Interference (RNAi) Drug Delivery Sales in Volume by Country (2017-2028) & (K Units)
    Table 37. Europe RNA Interference (RNAi) Drug Delivery Sales in Value by Country (2017-2028) & (US$ Million)
    Table 38. Latin America RNA Interference (RNAi) Drug Delivery Sales in Volume by Country (2017-2028) & (K Units)
    Table 39. Latin Americaa RNA Interference (RNAi) Drug Delivery Sales in Value by Country (2017-2028) & (US$ Million)
    Table 40. Middle East and Africa RNA Interference (RNAi) Drug Delivery Sales in Volume by Country (2017-2028) & (K Units)
    Table 41. Middle East and Africa RNA Interference (RNAi) Drug Delivery Sales in Value by Country (2017-2028) & (US$ Million)
    Table 42. Metabolic disorders Corporation Information
    Table 43. Metabolic disorders Description and Business Overview
    Table 44. Metabolic disorders RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 45. Metabolic disorders RNA Interference (RNAi) Drug Delivery Product
    Table 46. Metabolic disorders Recent Development
    Table 47. Alnylam Pharmaceuticals Inc Corporation Information
    Table 48. Alnylam Pharmaceuticals Inc Description and Business Overview
    Table 49. Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 50. Alnylam Pharmaceuticals Inc Product
    Table 51. Alnylam Pharmaceuticals Inc Recent Development
    Table 52. Merck & Co. Inc Corporation Information
    Table 53. Merck & Co. Inc Description and Business Overview
    Table 54. Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 55. Merck & Co. Inc Product
    Table 56. Merck & Co. Inc Recent Development
    Table 57. Access Pharmaceuticals Inc Corporation Information
    Table 58. Access Pharmaceuticals Inc Description and Business Overview
    Table 59. Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 60. Access Pharmaceuticals Inc Product
    Table 61. Access Pharmaceuticals Inc Recent Development
    Table 62. Dicerna Pharmaceuticals Inc Corporation Information
    Table 63. Dicerna Pharmaceuticals Inc Description and Business Overview
    Table 64. Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 65. Dicerna Pharmaceuticals Inc Product
    Table 66. Dicerna Pharmaceuticals Inc Recent Development
    Table 67. Calondo Pharmaceuticals Inc Corporation Information
    Table 68. Calondo Pharmaceuticals Inc Description and Business Overview
    Table 69. Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 70. Calondo Pharmaceuticals Inc Product
    Table 71. Calondo Pharmaceuticals Inc Recent Development
    Table 72. Marina Biotech Inc Corporation Information
    Table 73. Marina Biotech Inc Description and Business Overview
    Table 74. Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 75. Marina Biotech Inc Product
    Table 76. Marina Biotech Inc Recent Development
    Table 77. RXi Pharmaceuticals Corp Corporation Information
    Table 78. RXi Pharmaceuticals Corp Description and Business Overview
    Table 79. RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 80. RXi Pharmaceuticals Corp Product
    Table 81. RXi Pharmaceuticals Corp Recent Development
    Table 82. Quark Pharmaceuticals Inc Corporation Information
    Table 83. Quark Pharmaceuticals Inc Description and Business Overview
    Table 84. Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 85. Quark Pharmaceuticals Inc Product
    Table 86. Quark Pharmaceuticals Inc Recent Development
    Table 87. Silence Therapeutics plc Corporation Information
    Table 88. Silence Therapeutics plc Description and Business Overview
    Table 89. Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 90. Silence Therapeutics plc Product
    Table 91. Silence Therapeutics plc Recent Development
    Table 92. Tacere Therapeutics Inc Corporation Information
    Table 93. Tacere Therapeutics Inc Description and Business Overview
    Table 94. Tacere Therapeutics Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 95. Tacere Therapeutics Inc Product
    Table 96. Tacere Therapeutics Inc Recent Development
    Table 97. PhaseRx Inc Corporation Information
    Table 98. PhaseRx Inc Description and Business Overview
    Table 99. PhaseRx Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 100. PhaseRx Inc Product
    Table 101. PhaseRx Inc Recent Development
    Table 102. Sirnaomics Inc Corporation Information
    Table 103. Sirnaomics Inc Description and Business Overview
    Table 104. Sirnaomics Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 105. Sirnaomics Inc Product
    Table 106. Sirnaomics Inc Recent Development
    Table 107. Traversa Therapeutics Inc Corporation Information
    Table 108. Traversa Therapeutics Inc Description and Business Overview
    Table 109. Traversa Therapeutics Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 110. Traversa Therapeutics Inc Product
    Table 111. Traversa Therapeutics Inc Recent Development
    Table 112. Key Raw Materials Lists
    Table 113. Raw Materials Key Suppliers Lists
    Table 114. RNA Interference (RNAi) Drug Delivery Customers List
    Table 115. RNA Interference (RNAi) Drug Delivery Distributors List
    Table 116. Research Programs/Design for This Report
    Table 117. Key Data Information from Secondary Sources
    Table 118. Key Data Information from Primary Sources
List of Figures
    Figure 1. RNA Interference (RNAi) Drug Delivery Product Picture
    Figure 2. Global RNA Interference (RNAi) Drug Delivery Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global RNA Interference (RNAi) Drug Delivery Market Size 2017-2028 (US$ Million)
    Figure 4. Global RNA Interference (RNAi) Drug Delivery Sales 2017-2028 (K Units)
    Figure 5. United States RNA Interference (RNAi) Drug Delivery Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 6. United States RNA Interference (RNAi) Drug Delivery Market Size 2017-2028 (US$ Million)
    Figure 7. United States RNA Interference (RNAi) Drug Delivery Sales 2017-2028 (K Units)
    Figure 8. United States RNA Interference (RNAi) Drug Delivery Market Share in Global, in Value (US$ Million) 2017-2028
    Figure 9. United States RNA Interference (RNAi) Drug Delivery Market Share in Global, in Volume (K Units) 2017-2028
    Figure 10. RNA Interference (RNAi) Drug Delivery Report Years Considered
    Figure 11. Product Picture of Nanoparticle Drug Delivery Technology
    Figure 12. Product Picture of Pulmonary Drug Delivery Technology
    Figure 13. Product Picture of Nucleic Acid Drug Delivery Technology
    Figure 14. Product Picture of Aptamer Drug Delivery Technology
    Figure 15. Global RNA Interference (RNAi) Drug Delivery Market Share by Type in 2022 & 2028
    Figure 16. Global RNA Interference (RNAi) Drug Delivery Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 17. Global RNA Interference (RNAi) Drug Delivery Sales Market Share in Value by Type (2017-2028)
    Figure 18. Global RNA Interference (RNAi) Drug Delivery Sales by Type (2017-2028) & (K Units)
    Figure 19. Global RNA Interference (RNAi) Drug Delivery Sales Market Share in Volume by Type (2017-2028)
    Figure 20. Global RNA Interference (RNAi) Drug Delivery Price by Type (2017-2028) & (USD/Unit)
    Figure 21. United States RNA Interference (RNAi) Drug Delivery Market Share by Type in 2022 & 2028
    Figure 22. United States RNA Interference (RNAi) Drug Delivery Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 23. United States RNA Interference (RNAi) Drug Delivery Sales Market Share in Value by Type (2017-2028)
    Figure 24. United States RNA Interference (RNAi) Drug Delivery Sales by Type (2017-2028) & (K Units)
    Figure 25. United States RNA Interference (RNAi) Drug Delivery Sales Market Share in Volume by Type (2017-2028)
    Figure 26. United States RNA Interference (RNAi) Drug Delivery Price by Type (2017-2028) & (USD/Unit)
    Figure 27. Product Picture of Infectious Diseases
    Figure 28. Product Picture of Cardiology
    Figure 29. Product Picture of Oncology
    Figure 30. Product Picture of Neurology
    Figure 31. Product Picture of Ophthalmology
    Figure 32. Product Picture of Metabolic Disorders
    Figure 33. Global RNA Interference (RNAi) Drug Delivery Market Share by Application in 2022 & 2028
    Figure 34. Global RNA Interference (RNAi) Drug Delivery Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 35. Global RNA Interference (RNAi) Drug Delivery Sales Market Share in Value by Application (2017-2028)
    Figure 36. Global RNA Interference (RNAi) Drug Delivery Sales by Application (2017-2028) & (K Units)
    Figure 37. Global RNA Interference (RNAi) Drug Delivery Sales Market Share in Volume by Application (2017-2028)
    Figure 38. Global RNA Interference (RNAi) Drug Delivery Price by Application (2017-2028) & (USD/Unit)
    Figure 39. United States RNA Interference (RNAi) Drug Delivery Market Share by Application in 2022 & 2028
    Figure 40. United States RNA Interference (RNAi) Drug Delivery Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 41. United States RNA Interference (RNAi) Drug Delivery Sales Market Share in Value by Application (2017-2028)
    Figure 42. United States RNA Interference (RNAi) Drug Delivery Sales by Application (2017-2028) & (K Units)
    Figure 43. United States RNA Interference (RNAi) Drug Delivery Sales Market Share in Volume by Application (2017-2028)
    Figure 44. United States RNA Interference (RNAi) Drug Delivery Price by Application (2017-2028) & (USD/Unit)
    Figure 45. North America RNA Interference (RNAi) Drug Delivery Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 46. North America RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 47. U.S. RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Canada RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 49. Europe RNA Interference (RNAi) Drug Delivery Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 50. Europe RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 51. Germany RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 52. France RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 53. U.K. RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Italy RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 55. Russia RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 56. Asia-Pacific RNA Interference (RNAi) Drug Delivery Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 57. Asia-Pacific RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 58. China RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 59. Japan RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 60. South Korea RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 61. India RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 62. Australia RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 63. Taiwan RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 64. Indonesia RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 65. Thailand RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 66. Malaysia RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 67. Philippines RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 68. Latin America RNA Interference (RNAi) Drug Delivery Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 69. Latin America RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 70. Mexico RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 71. Brazil RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 72. Argentina RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 73. Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 74. Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 75. Turkey RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 76. Saudi Arabia RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 77. U.A.E RNA Interference (RNAi) Drug Delivery Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 78. RNA Interference (RNAi) Drug Delivery Value Chain
    Figure 79. RNA Interference (RNAi) Drug Delivery Production Process
    Figure 80. Channels of Distribution
    Figure 81. Distributors Profiles
    Figure 82. Bottom-up and Top-down Approaches for This Report
    Figure 83. Data Triangulation
    Figure 84. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Metabolic disorders
Alnylam Pharmaceuticals Inc
Merck & Co. Inc
Access Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc
Calondo Pharmaceuticals Inc
Marina Biotech Inc
RXi Pharmaceuticals Corp
Quark Pharmaceuticals Inc
Silence Therapeutics plc
Tacere Therapeutics Inc
PhaseRx Inc
Sirnaomics Inc
Traversa Therapeutics Inc
Frequently Asked Questions
RNA Interference (RNAi) Drug Delivery report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
RNA Interference (RNAi) Drug Delivery report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
RNA Interference (RNAi) Drug Delivery report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Baby Mosquito Net

Baby Mosquito Net market is segmented by region (country), players, by Type and by Application. P ... Read More